AI's Rising Influence in Ophthalmology: A Market Set for Growth

Published Date : 23-07-2025 

The AI in Ophthalmology Market, valued at USD 209.23 million in 2024, is projected to reach USD 1.36 billion by 2030, driven by advancements in imaging technology and teleophthalmology. 

The AI in Ophthalmology Market, valued at USD 209.23 million in 2024, is projected to reach USD 1.36 billion by 2030, growing at a CAGR of 36.79%. This significant growth is driven by several factors, including the rising prevalence of eye diseases, advancements in imaging technology, and the expansion of teleophthalmology services.

The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, is a significant driver of the market. As the population ages, the incidence of these diseases increases, creating a need for efficient and accurate diagnostic tools. For instance, according to the CDC, the estimated number of Americans living with glaucoma in 2022 was 4.22 million.

AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment. For example, AI systems have shown high sensitivity and specificity in identifying diabetic retinopathy, allowing for timely interventions and reducing the risk of vision loss. Moreover, integrating advanced imaging techniques such as Optical Coherence Tomography (OCT) with AI has revolutionized ophthalmic diagnostics. High-resolution imaging provides detailed views of ocular structures, enhancing diagnostic precision when analyzed by artificial intelligence (AI). The availability of large datasets from these imaging technologies allows for the training of robust AI models, improving their accuracy and reliability in clinical settings.

Teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech startup, raised USD 0.23 million to launch AI-enabled, portable eye screening devices. The funding is expected to support telemedicine integration, real-time disease detection, and expansion across India, aiming to reduce avoidable blindness, especially in underserved communities facing a shortage of ophthalmologists.

AI's ability to analyze and interpret data from Electronic Health Records (EHRs) facilitates personalized treatment plans in ophthalmology. AI predicts disease progression by assessing patient history, genetic information, and imaging data and recommends tailored interventions, further contributing to market growth. Active healthcare/tech companies in this industry include Avant Technologies Inc., Alcon Inc., Bausch + Lomb Corporation, Johnson & Johnson, and Tempus AI, Inc.

Avant Technologies, Inc., an emerging technology company developing healthcare solutions using AI, has a joint venture partner that presented AI technology at Roche's Ophthalmology Conference in Cartagena, Colombia. Ainnova's CEO, Vinicio Vargas, discussed the status of AI and its uses in the industry to improve patient outcomes. Ainnova entered a strategic alliance with Roche and Salud 360 to start a pilot program to combat diabetic retinopathy using AI-powered technology, Vision AI.

Alcon Inc., a global leader in eye care, recently announced that the UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio, marking a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients.

Bausch + Lomb Corporation, a leading global eye health company, launched the 

Frequently Asked Questions (FAQS): 

Q: What is the projected market value of AI in Ophthalmology by 2030?

A: The AI in Ophthalmology Market is projected to reach USD 1.36 billion by 2030.

Q: What are the key drivers of the AI in Ophthalmology Market?

A: The key drivers include the rising prevalence of eye diseases, advancements in imaging technology, and the expansion of teleophthalmology services.

Q: How does AI improve early detection of eye diseases?

A: AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment, particularly for conditions like diabetic retinopathy.

Q: What is the significance of teleophthalmology in this market?

A: Teleophthalmology increases access to eye care, especially in underserved regions, by enabling automated analysis of retinal images and remote diagnosis.

Q: Which companies are leading the way in AI for ophthalmology?

A: Leading companies in this field include Avant Technologies Inc., Alcon Inc., Bausch + Lomb Corporation, Johnson & Johnson, and Tempus AI, Inc. 

More Related Topics :